Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best doses of abemaciclib and cabozantinib to use in people with advanced kidney cancer. The people in this study have clear cell renal cell carcinoma that metastasized (spread); they previously received other kidney cancer therapies. In addition, their cancer keeps growing even after 2 or 3 prior treatments, including checkpoint inhibitor immunotherapy.
Researchers want to find the best dose of ADCE-D01 to treat soft tissue sarcoma. In this study, we treat people with soft tissue sarcoma that is inoperable (cannot be surgically removed) or metastasized (spread).
Researchers are assessing different doses of CHS-114 when combined with toripalimab in people with advanced digestive cancers. The people in this study have digestive cancers that have metastasized (spread) or are inoperable (cannot be surgically removed). These cancers include:
The purpose of this study is to find the highest dose of the investigational drug CA-4948 that can be given safely and to evaluate its preliminary anticancer effectiveness in patients with non-Hodgkin lymphoma that has come back or continued to grow despite prior therapy. CA-4948 works by blocking a protein in normal and cancerous B cells (a type of immune cell) called IRAK4, which may promote the growth and survival of B cells in lymphoma. CA-4948 is designed to fight cancer by blocking IRAK4, thereby stopping or reducing the signals that promote lymphoma B-cell survival.
Researchers want to learn if AMG 193 in combination with standard treatment is safe for people with advanced pancreatic cancer. The people in this study have pancreatic ductal adenocarcinoma (PDAC) that has metastasized (spread). In addition, their cancers have a mutation (change) in the MTAP gene. This results in a lack of the MTAP protein, which may help cancer grow.
Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.
Researchers want to find the best dose of AZD0305 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. AZD0305 is given intravenously (by vein).
Researchers are measuring the safety of ivonescimab when given with standard lung cancer treatments and seeing how well it works. The people in this study have been newly diagnosed with squamous non-small cell lung cancer that has metastasized (spread).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).
